BIOLIFE SOLUTIONS INC BLFS
We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution.
We currently operate as one bioproduction products and services business which supports several steps in the biologic material manufacturing and delivery process. Our portfolio of tools and services focuses on biopreservation media and cell processing products. We have in-house expertise in cryobiology and the broader CGT workflow, and continue to evaluate opportunities to maximize the value of our product platforms for our extensive customer base through organic growth innovations, partnerships, and acquisitions.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | $119.2M | $48.1M | $27.4M | $19.7M | $11.0M | $8.2M |
| Cost of revenue | $34.1M | $24.6M | $26.7M | — | — | — | $8.8M | $6.2M | $4.3M | $3.4M |
| Gross profit | $62.1M | $50.1M | $41.3M | — | — | — | $18.6M | $13.5M | $6.7M | $4.8M |
| R&D | $7.6M | $4.8M | $5.5M | $8.7M | $11.8M | $6.7M | $3.2M | $1.3M | $1.2M | $2.0M |
| SG&A | $45.5M | $40.6M | $42.8M | $33.3M | $33.7M | $15.3M | $8.9M | $6.0M | $4.5M | $4.6M |
| Total operating expenses | $78.7M | $54.6M | $58.5M | $82.2M | $154.3M | $54.3M | $27.6M | $16.1M | $7.8M | $9.6M |
| Operating income | -$16.6M | -$4.5M | -$17.2M | -$5.9M | -$35.2M | -$6.2M | -$220.0K | $3.7M | -$1.1M | -$4.9M |
| Interest expense | — | — | — | — | — | — | $5.0K | $5.0K | $190.0K | $100.0K |
| Pre-tax income | -$12.1M | -$8.8M | -$12.2M | -$4.8M | -$29.0M | -$1.3M | -$3.2M | -$25.0M | -$2.5M | -$6.9M |
| Income tax | $49.0K | $38.0K | $64.0K | $5.2M | $20.1M | $3.3M | $1.5M | — | $0 | $0 |
| Net income | -$4.6M | -$20.2M | -$68.0M | -$139.8M | -$8.9M | $2.0M | -$1.7M | -$25.0M | -$2.5M | -$6.9M |
| EPS, basic | -0.09 | -0.44 | -1.55 | -3.29 | -0.23 | 0.07 | -0.09 | -1.56 | -0.21 | — |
| EPS, diluted | -0.10 | -0.44 | -1.55 | -3.25 | -0.23 | -0.06 | -0.09 | -1.56 | -0.21 | -0.54 |
| Shares, diluted (wtd. avg.) | 48.6M | 46.1M | 43.7M | 43.1M | 38.5M | 27.3M | 19.5M | 16.3M | 13.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $33.0M | $91.5M | $27.9M | $19.4M | $69.9M | $90.4M | $6.4M | $14.2M | $6.7M | $1.4M |
| Short-term investments | $55.9M | $9.2M | $16.3M | $43.3M | $0 | — | — | — | — | $0 |
| Receivables | $8.0M | $8.5M | $7.9M | $33.9M | $23.2M | $8.0M | $5.3M | $2.2M | $1.0M | $1.2M |
| Inventory | $30.2M | $29.0M | $27.2M | $34.9M | $28.3M | $11.6M | $11.0M | $2.1M | $1.8M | $1.8M |
| Total current assets | $136.6M | $148.8M | $120.6M | $138.5M | $126.1M | $114.7M | $24.1M | $18.8M | $10.2M | $4.6M |
| Property, plant and equipment | $14.7M | $6.0M | $5.7M | $23.6M | $17.7M | $10.1M | $5.6M | $1.0M | $1.1M | $1.2M |
| Goodwill | $208.6M | $208.6M | $212.3M | $224.7M | $58.4M | $58.4M | $33.6M | $0 | — | — |
| Other intangibles | $4.3M | $5.6M | $12.0M | $32.1M | $152.1M | $31.0M | $22.0M | — | — | $0 |
| Total assets | $405.9M | $399.5M | $412.7M | $450.2M | $554.3M | $234.8M | $92.8M | $21.8M | $12.3M | $7.9M |
| Accounts payable | $1.5M | $3.4M | $2.3M | $15.4M | $14.9M | $3.7M | $3.1M | $843.0K | $586.0K | $710.7K |
| Short-term debt | $5.0M | $10.9M | $6.3M | $1.8M | $862.0K | $614.0K | — | — | — | — |
| Total current liabilities | $23.0M | $32.7M | $42.2M | $44.6M | $42.7M | $15.6M | $7.7M | $1.7M | $1.3M | $1.1M |
| Long-term debt | $0 | $5.0M | $17.6M | $23.8M | $6.4M | $655.0K | $13.0K | — | — | $4.2M |
| Total liabilities | $34.0M | $50.6M | $75.1M | $86.0M | $76.2M | $29.6M | $49.4M | $34.7M | $16.5M | $4.8M |
| Retained earnings | -$339.7M | -$335.1M | -$314.9M | -$246.9M | -$107.1M | -$97.4M | $100.2M | -$94.7M | -$73.1M | -$71.2M |
| Total equity | $371.9M | $348.9M | $337.7M | $364.2M | $478.0M | $204.4M | $43.3M | $14.6M | -$9.5M | $3.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $20.1M | $8.4M | -$12.5M | -$8.5M | -$4.6M | $6.6M | $1.2M | $2.3M | $605.0K | -$4.3M |
| Depreciation and amortisation | $2.3M | $5.2M | $7.1M | $6.8M | $4.7M | $2.0M | $718.0K | $338.0K | $339.0K | $368.1K |
| Stock-based compensation | $23.0M | $30.9M | $33.2M | $25.3M | $14.0M | $6.0M | $3.0M | $1.5M | $1.3M | $777.0K |
| Capital expenditure | $9.5M | $3.2M | $6.4M | $10.4M | $8.4M | $2.0M | $675.0K | $500.0K | $144.0K | $143.5K |
| Investing cash flow | -$71.5M | $58.3M | $17.8M | -$58.1M | -$13.2M | -$24.7M | -$27.0M | -$6.5M | -$144.0K | $392.8K |
| Financing cash flow | -$10.9M | -$6.8M | $10.6M | $16.3M | -$2.8M | $102.1M | $1.6M | $28.1M | $4.8M | $3.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028012.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M | $11.0M | $19.7M | $27.4M | $48.1M | $119.2M | $76.2M | $68.0M | $74.6M | $96.2M |
| Gross profit | $4.8M | $6.7M | $13.5M | $18.6M | — | — | — | $41.3M | $50.1M | $62.1M |
| Net income | -$6.9M | -$2.5M | -$25.0M | -$1.7M | $2.0M | -$8.9M | -$139.8M | -$68.0M | -$20.2M | -$4.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| LIVN | LivaNova PLC | $4.46B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |
| CV | CapsoVision, Inc | $349.8M | — | 15.3% |